suramin has been researched along with Autoimmune Demyelinating Disease, Peripheral in 1 studies
Suramin: A polyanionic compound with an unknown mechanism of action. It is used parenterally in the treatment of African trypanosomiasis and it has been used clinically with diethylcarbamazine to kill the adult Onchocerca. (From AMA Drug Evaluations Annual, 1992, p1643) It has also been shown to have potent antineoplastic properties.
suramin : A member of the class of phenylureas that is urea in which each of the amino groups has been substituted by a 3-({2-methyl-5-[(4,6,8-trisulfo-1-naphthyl)carbamoyl]phenyl}carbamoyl)phenyl group. An activator of both the rabbit skeletal muscle RyR1 and sheep cardiac RyR2 isoform ryanodine receptor channels, it has been used for the treatment of human African trypanosomiasis for over 100 years.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Schröder, JM | 1 |
| Toyka, KV | 1 |
| Hartung, HP | 1 |
1 other study available for suramin and Autoimmune Demyelinating Disease, Peripheral
| Article | Year |
|---|---|
11th meeting of the Peripheral Nerve Study Group (PNSG). "Klostergut Jakobsberg", Boppard, Germany 29 July-1 August 1993.
Topics: Animals; Cytokines; Humans; Neuritis; Neurons; Peripheral Nervous System Diseases; Polyradiculoneuro | 1995 |